Literature DB >> 19688981

Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma.

Sara De Dosso1, Luca Mazzucchelli, Michele Ghielmini, Piercarlo Saletti.   

Abstract

Esophageal localization of adenoid cystic carcinoma of minor salivary glands is rare; it may occur in the early to mid-sixties' age group and is more frequently encountered in men than women. In the majority of cases, it arises from subepithelial glands of the middle to lower third of the esophagus, a similar distribution as squamous cell carcinoma. Prognosis depends mostly on tumor staging and resectability, which represents the only chance of cure. Due to the extreme rarity of this condition, there is limited experience with systemic therapy for advanced disease. We report a case of a patient with metastatic primary esophageal adenoid cystic carcinoma progressing on platinum- and irinotecan-based regimens, who achieved an objective response with oxaliplatin-based chemotherapy in combination with cetuximab.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688981     DOI: 10.1177/030089160909500319

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.

Authors:  Tatsuo Masubuchi; Yuichiro Tada; Shin-ichiro Maruya; Yoshiyuki Osamura; Shin-etsu Kamata; Kouki Miura; Chihiro Fushimi; Hideaki Takahashi; Daisuke Kawakita; Seiji Kishimoto; Toshitaka Nagao
Journal:  Int J Clin Oncol       Date:  2014-02-20       Impact factor: 3.402

2.  Chemoradiotherapy with irinotecan (CPT-11) for adenoid cystic carcinoma of Bartholin's gland: A case report and review of the literature.

Authors:  Eriko Takatori; Tadahiro Shoji; Jiyu Miura; Satoshi Takeuchi; Toru Sugiyama
Journal:  Gynecol Oncol Case Rep       Date:  2012-12-14

3.  Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.

Authors:  E Hitre; B Budai; Z Takácsi-Nagy; G Rubovszky; E Tóth; É Remenár; C Polgár; I Láng
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.